113 related articles for article (PubMed ID: 18653746)
1. Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase.
Wei X; Dai G; Liu Z; Cheng H; Xie Z; Klisovic R; Marcucci G; Chan KK
Drug Metab Dispos; 2008 Nov; 36(11):2227-33. PubMed ID: 18653746
[TBL] [Abstract][Full Text] [Related]
2. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2.
Ferdinandi ES; Vassilakos A; Lee Y; Lightfoot J; Fitsialos D; Wright JA; Young AH
Cancer Chemother Pharmacol; 2011 Jul; 68(1):193-205. PubMed ID: 20886212
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Klisovic RB; Blum W; Wei X; Liu S; Liu Z; Xie Z; Vukosavljevic T; Kefauver C; Huynh L; Pang J; Zwiebel JA; Devine S; Byrd JC; Grever MR; Chan K; Marcucci G
Clin Cancer Res; 2008 Jun; 14(12):3889-95. PubMed ID: 18559610
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry.
Wei X; Dai G; Liu Z; Cheng H; Xie Z; Marcucci G; Chan KK
AAPS J; 2006; 8(4):E743-55. PubMed ID: 17285740
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
Jin Y; Liu S; Yu B; Golan S; Koh CG; Yang J; Huynh L; Yang X; Pang J; Muthusamy N; Chan KK; Byrd JC; Talmon Y; Lee LJ; Lee RJ; Marcucci G
Mol Pharm; 2010 Feb; 7(1):196-206. PubMed ID: 19852511
[TBL] [Abstract][Full Text] [Related]
6. Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
Chen P; Aimiuwu J; Xie Z; Wei X; Liu S; Klisovic R; Marcucci G; Chan KK
AAPS J; 2011 Mar; 13(1):131-40. PubMed ID: 21191677
[TBL] [Abstract][Full Text] [Related]
7. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
Kirschbaum MH; Frankel P; Synold TW; Xie Z; Yen Y; Popplewell L; Chen R; Aljitawi O; Tuscano JM; Chan KK; Newman EM
Leuk Lymphoma; 2016 Oct; 57(10):2307-14. PubMed ID: 26895565
[TBL] [Abstract][Full Text] [Related]
8. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
[TBL] [Abstract][Full Text] [Related]
9. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
Li H; Xu S; Quan J; Yung BC; Pang J; Zhou C; Cho YA; Zhang M; Liu S; Muthusamy N; Chan KK; Byrd JC; Lee LJ; Marcucci G; Lee RJ
Mol Pharm; 2015 Jun; 12(6):2010-8. PubMed ID: 25871632
[TBL] [Abstract][Full Text] [Related]
10. GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
Lee Y; Vassilakos A; Feng N; Jin H; Wang M; Xiong K; Wright J; Young A
Int J Oncol; 2006 Feb; 28(2):469-78. PubMed ID: 16391803
[TBL] [Abstract][Full Text] [Related]
11. In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes.
Carlile DJ; Stevens AJ; Ashforth EI; Waghela D; Houston JB
Drug Metab Dispos; 1998 Mar; 26(3):216-21. PubMed ID: 9492383
[TBL] [Abstract][Full Text] [Related]
12. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.
Gallagher EP; Kunze KL; Stapleton PL; Eaton DL
Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785
[TBL] [Abstract][Full Text] [Related]
13. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
Desta Z; Wu GM; Morocho AM; Flockhart DA
Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
[TBL] [Abstract][Full Text] [Related]
14. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.
Witherow LE; Houston JB
J Pharmacol Exp Ther; 1999 Jul; 290(1):58-65. PubMed ID: 10381760
[TBL] [Abstract][Full Text] [Related]
15. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide.
Kumar S; Samuel K; Subramanian R; Braun MP; Stearns RA; Chiu SH; Evans DC; Baillie TA
J Pharmacol Exp Ther; 2002 Dec; 303(3):969-78. PubMed ID: 12438516
[TBL] [Abstract][Full Text] [Related]
16. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance.
Brown HS; Griffin M; Houston JB
Drug Metab Dispos; 2007 Feb; 35(2):293-301. PubMed ID: 17132764
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
Casabar RC; Wallace AD; Hodgson E; Rose RL
Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Stadler WM; Desai AA; Quinn DI; Bukowski R; Poiesz B; Kardinal CG; Lewis N; Makalinao A; Murray P; Torti FM
Cancer Chemother Pharmacol; 2008 Apr; 61(4):689-94. PubMed ID: 17569043
[TBL] [Abstract][Full Text] [Related]
20. Identification of cytochrome P450 isoenzymes involved in metabolism of (+)-praeruptorin A, a calcium channel blocker, by human liver microsomes using ultra high-performance liquid chromatography coupled with tandem mass spectrometry.
Jing WH; Song YL; Yan R; Wang YT
J Pharm Biomed Anal; 2013 Apr; 77():175-88. PubMed ID: 23434495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
